Albany, New York, May 31, 2018: The global proliferative diabetic retinopathy market is likely to grow at a CAGR of 9.5% during the assessment period 2017-2026, on account of a range of macroeconomic and industry-specific factors. According to the report, the proliferative diabetic retinopathy market is likely to reach a valuation of nearly US$ 1 Bn by the end of 2026. The research report titled “Proliferative Diabetic Retinopathy Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2026” has been added to the vast repository of Market Research Reports Search Engine (MRRSE).
According to the research study, over 150 Mn individuals globally are at the risk of developing diabetic retinopathy, and a significant percentage of them are also at risk of developing proliferative diabetic retinopathy. The increase in the geriatric population is also likely to create new growth opportunities for manufacturers in this market. According to the research study, the increasing baby boomer population around the world is putting significant pressures on the healthcare sector, and it is also creating opportunities for vendors in this landscape.
In a bid to offer reads in-depth insights on the market, the research study offers detailed segment-wise analysis and forecast. On the basis of drug class, the key segments include anti-VEGF agents and corticosteroids. By mode of administration, the key segments include injectables, oral, and others. The research study also offers analysis on the basis of distribution channel. The key segments on the basis of distribution channel include hospital pharmacies, retail pharmacies, and online pharmacies. The region-wise segmentation and analysis includes North America, Latin America, Europe, Japan, APEJ, and MEA.
According to the study, North America continues to be one of the leading markets for proliferative diabetic retinopathy globally. The demand for proliferative diabetic retinopathy in North America is concentrated in the US, whereas Canada accounts for a miniscule revenue share. In addition to North America, Asia Pacific excluding Japan (APEJ) is another lucrative market for proliferative diabetic retinopathy globally. The market in APEJ is driven by growing emphasis on providing quality healthcare services to the growing populace.
The business intelligence study also offers in-depth analysis and insights on the competitive landscape in the market. According to the study, some of the leading players in the market include Pfizer, Inc., Genentech, Inc. (Roche Holdings), Merck KGaA, Allergan Plc, Santen Pharmaceutical Co., Ltd., Cipla, Ltd., Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Intas Pharmaceuticals Limited, and Novartis AG.
Browse Full Global Proliferative Diabetic Retinopathy Market Report with TOC : https://www.mrrse.com/proliferative-diabetic-retinopathy-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207